stoxline Quote Chart Rank Option Currency Glossary
  
scPharmaceuticals Inc. (SCPH)
5.02  -0.01 (-0.2%)    03-28 16:00
Open: 5.05
High: 5.155
Volume: 110,060
  
Pre. Close: 5.03
Low: 4.97
Market Cap: 181(M)
Technical analysis
2024-03-28 4:54:09 PM
Short term     
Mid term     
Targets 6-month :  6.88 1-year :  7.63
Resists First :  5.89 Second :  6.53
Pivot price 5.29
Supports First :  4.84 Second :  4.02
MAs MA(5) :  4.99 MA(20) :  5.44
MA(100) :  5.59 MA(250) :  7.41
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  10.7 D(3) :  8.5
RSI RSI(14): 41
52-week High :  12.75 Low :  4.63
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SCPH ] has closed above bottom band by 22.8%. Bollinger Bands are 2.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.16 - 5.19 5.19 - 5.22
Low: 4.9 - 4.93 4.93 - 4.96
Close: 4.97 - 5.03 5.03 - 5.07
Company Description

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Headline News

Wed, 27 Mar 2024
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62% - Yahoo Finance

Wed, 27 Mar 2024
American Century Companies Inc. Sells 15647 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World

Mon, 25 Mar 2024
scPharmaceuticals Inc. (NASDAQ:SCPH) stock most popular amongst private equity firms who own 41%, while ... - Yahoo Movies UK

Mon, 18 Mar 2024
Research Analysts Offer Predictions for scPharmaceuticals Inc.'s FY2028 Earnings (NASDAQ:SCPH) - Defense World

Sat, 16 Mar 2024
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts - Simply Wall St

Wed, 13 Mar 2024
scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 36 (M)
Shares Float 18 (M)
Held by Insiders 6.9 (%)
Held by Institutions 75.9 (%)
Shares Short 4,790 (K)
Shares Short P.Month 4,670 (K)
Stock Financials
EPS -1.42
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.02
Profit Margin 0 %
Operating Margin -250.3 %
Return on Assets (ttm) -31.7 %
Return on Equity (ttm) -100 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.37
EBITDA (p.s.) -1.54
Qtrly Earnings Growth 0 %
Operating Cash Flow -59 (M)
Levered Free Cash Flow -40 (M)
Stock Valuations
PE Ratio -3.54
PEG Ratio 0
Price to Book value 4.87
Price to Sales 13.31
Price to Cash Flow -3.06
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android